Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET
Abstract
Atypical teratoid/rhabdoid tumors (AT/RT) and central nervous system primitive neuroectodermal tumors (CNS-PNET) are pediatric brain tumors with poor survival and life-long negative side effects. Here, the aim was to characterize the efficacy and safety of the oncolytic adenovirus, Delta-24-RGD, which selectively replicates in and kills tumor cells.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 29, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-3313
Entities
People
- Ana Patiño-García
- Candelaria Gomez-Manzano
- Carlos De Andrea
- Elizabeth Guruceaga
- Eric H. Raabe
- Eva Bandres
- Ignacio Iñigo-marco
- Jaime Gállego Pérez-Larraya
- Jennifer A Chan
- Juan Fueyo
- Lucia Marrodan
- Marc Garcia-Moure
- Marcel Kool
- Maria Villalba
- Marisol Gonzalez-Huarriz
- Marta M Alonso
- Montse Puigdelloses
- Naiara Martínez-vélez
- Renata Stripecke
- Sara Labiano
- Virginia Laspidea
Organizations
- Carlos III Health Institute
- Clínica Universidad de Navarra
- European Commission
- German Cancer Research Center
- Johns Hopkins School of Medicine
- United States Department of Defense
- University of Calgary
- University of Texas at Austin